Study of Toripalimab and 9MW2821 before surgery for local UTUC
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two drugs (toripalimab and 9MW2821) given before surgery for patients with upper tract urothelial cancer that hasn't spread. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with upper tract urothelial cancer that hasn't spread to other parts of the body (stage T1, T2, or T3).
- You are able and willing to have surgery to remove the affected kidney and ureter.
- You have not had any prior chemotherapy, immunotherapy, or other systemic cancer treatment for this cancer.
- You have good overall health (able to do daily activities without significant help) and adequate organ function.
- You can provide a tumor tissue sample for testing and agree to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
This trial is testing a system that helps doctors choose the best additional treatment for people with advanced upper tract urothelial cancer (UTUC) after their surgery. It focuses on patients whose cancer has spread into the muscle layer or beyond, or to nearby lymph nodes.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.